Drug company Aspen faces probe over hiking generic pricesBMJ 2017; 357 doi: https://doi.org/10.1136/bmj.j2417 (Published 18 May 2017) Cite this as: BMJ 2017;357:j2417
- Nigel Hawkes
The European Commission has launched an investigation into increased prices on cancer drugs imposed by Aspen, a South African company.
Aspen acquired five drugs from GlaxoSmithKline (GSK) in 2009 in a deal worth $2.2bn (then about £1.4bn) in cash and shares. Aspen increased the UK price of busulfan, a leukaemia drug, from £5.20 to £69.02 a pack. Chlorambucil, also used in leukaemia treatments, rose from £8.36 to £42.87.
Margrethe Vestager, the EU’s competition commissioner, said that people depended on drugs “to save or prolong our lives” and that, “when the price of a drug suddenly goes up by several hundred percent, this is something the commission may look at. More specifically, in this case we will be …
Log in using your username and password
Log in through your institution
Sign up for a free trial